Benevolent
At Benevolent we build technology in the service of science - to augment human intelligence and inspire the discovery of new medicines for the thousands of diseases that have no treatment. Building the right team is an art not a science. We strive to bring together unique skills and perspectives across biology, chemistry, engineering, AI research, informatics, precision medicine and drug discovery. We search for driven people who are not afraid to be challenged - who want to tackle the most demanding problems and are willing to embrace new ideas. We are an eclectic bunch, united by our belief that innovative thinking and purposeful technology can truly change outcomes for the better.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
About us
Building a healthier world in which no disease goes untreated
This is not a world that will emerge; it is a world we must create. So we’re building technology in the service of science in order to deliver life-changing medicines for patients in need.
What we do
Uniting human and machine intelligence to discover new ways to treat disease
We have pioneered a fundamentally unique approach to AI-drug discovery. It begins with the belief that all biomedical information is valuable, so we analyse all relevant data sets from multiple and diverse modalities. Our computational R&D platform spans from data through to discovery and clinical development, enabling us to better understand the mysteries of human disease and increase the probability of discovering a successful drug.
A foundation built on all the world’s relevant biomedical data
Our Knowledge Graph incorporates the entire corpus of relevant, publicly available data and is continuously enriched by in-house experimental results. Our models extract and derive new insights which power our platform tools and build a clearer picture of disease.
Fusing deep tech and scientific expertise to drive innovation
We bring together deep technology and scientific expertise into a work culture that promotes continuous innovation and enables ideas to progress faster.
Expanding AI capabilities across every stage of drug discovery
We expand AI across every step of the drug discovery process, encompassing target identification, small molecule drug discovery and patient stratification as we progress our portfolio of assets through clinical development.
Our disease agnostic approach removes therapeutic data silos
We remove the bias and conventional boundaries and silos attributed to a specific pathway, disease, or therapeutic area, opening up a diverse disease space for exploration and experimentation.
A mechanistic focus to tackle complex multifactorial diseases
Detailed mechanistic representations chart the interconnectivity of biology, enabling our scientists to investigate the aetiology of complex multifactorial diseases and find novel and optimal points of intervention.